Newsfeeds Archive - Spark Newswire

1 minute read

PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value

May 21, 9:41 AM

Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the

MYMD

2 minute read

PharmaCyte Biotech Acquires $5M Stake In Emerging Women’s Health Innovator Femasys, Inc.

By Benzinga Newsdesk

November 15, 9:34 AM

New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made

FEMY

2 minute read

PharmaCyte Biotech Provides Corporate Update On Cell-In-A-Box Technology

By Benzinga Newsdesk

October 31, 9:22 AM

Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunitiesPharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company")

PMCB

25 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

September 26, 12:04 PM

On Tuesday, 386 stocks made new 52-week lows.

$TKO

2 minute read

News

Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase Federal Funding For Pancreatic Cancer Research

By Benzinga Newsdesk

June 14, 9:13 AM

Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June 14, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer patient

ARAV

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

May 11, 9:06 AM

Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 45.1% to $0.77 during Thursday’s pre-market session. The company’s market cap stands…

AMPE

3 minute read

PharmaCyte Biotech Announces Cash Tender Offer For Up To 7.75M Shares At $3.25 Per Share

By Happy Mohamed

May 11, 8:35 AM

Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the

PMCB

1 minute read

News

PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation

By Benzinga Newsdesk

July 28, 12:45 PM

https://pharmacyte.com/pharmacyte-biotech-rebukes-iroquois-commencement-of-consent-solicitation/

PMCB

2 minute read

PharmaCyte Biotech Reports Interim Results in Malignant Ascites Mouse Model Study

By Bill Haddad

July 19, 8:33 AM

PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology,

PMCB